fluvastatin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors	1229	93957-54-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lescol fluvastatin leschol fluvastatin sodium XU-62-320 fluvastatin sodium salt fluvastatin sodium hydrate	An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4. Molecular weight: 411.47 Formula: C24H26FNO4 CLOGP: 4.05 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 82.69 ALOGS: -4.97 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lescol
fluvastatin
leschol
fluvastatin sodium
XU-62-320
fluvastatin sodium salt
fluvastatin sodium hydrate

An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.

Molecular weight: 411.47
Formula: C24H26FNO4
CLOGP: 4.05
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 82.69
ALOGS: -4.97
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.62 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	24 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.42 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	16 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.70 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 31, 1993	FDA	NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	144.65	14.68	138	8736	131887	56151306
Rhabdomyolysis	121.12	14.68	77	8797	40581	56242612
Blood creatine phosphokinase increased	117.26	14.68	66	8808	27886	56255307
Limb reduction defect	101.75	14.68	21	8853	366	56282827
Dysmorphism	73.72	14.68	23	8851	2190	56281003
Cleft palate	72.51	14.68	19	8855	966	56282227
Gamma-glutamyltransferase increased	66.65	14.68	48	8826	30957	56252236
Atrial septal defect	65.66	14.68	28	8846	6478	56276715
Talipes	65.34	14.68	19	8855	1423	56281770
Patent ductus arteriosus	60.66	14.68	23	8851	3928	56279265
Limb hypoplasia congenital	59.52	14.68	12	8862	185	56283008
Antinuclear antibody negative	58.42	14.68	12	8862	204	56282989
Congenital oral malformation	53.72	14.68	11	8863	184	56283009
Coombs positive haemolytic anaemia	52.86	14.68	12	8862	332	56282861
Alanine aminotransferase increased	50.78	14.68	68	8806	93594	56189599
Drug ineffective	50.23	14.68	43	8831	918946	55364247
Retrognathia	49.84	14.68	12	8862	431	56282762
Aspartate aminotransferase increased	49.48	14.68	63	8811	82539	56200654
Herpes simplex reactivation	48.39	14.68	12	8862	488	56282705
Developmental hip dysplasia	45.24	14.68	14	8860	1297	56281896
Myopathy	43.38	14.68	24	8850	9788	56273405
Acute kidney injury	41.09	14.68	106	8768	240657	56042536
Antiphospholipid syndrome	38.35	14.68	13	8861	1608	56281585
Gastritis haemorrhagic	36.02	14.68	12	8862	1407	56281786
Neck deformity	35.45	14.68	13	8861	2022	56281171
Rheumatoid arthritis	34.34	14.68	9	8865	382595	55900598
Lactic acidosis	33.11	14.68	34	8840	35312	56247881
Pancreatitis acute	32.73	14.68	29	8845	25095	56258098
Jaundice	32.60	14.68	30	8844	27264	56255929
Complex regional pain syndrome	31.30	14.68	12	8862	2111	56281082
Anxiety disorder	30.66	14.68	14	8860	3806	56279387
Premature baby	28.74	14.68	24	8850	19181	56264012
Interstitial lung disease	28.74	14.68	40	8834	57023	56226170
Off label use	27.92	14.68	28	8846	556152	55727041
Blood alkaline phosphatase increased	27.01	14.68	32	8842	38913	56244280
Aplasia	26.99	14.68	13	8861	3983	56279210
Muscle spasms	26.03	14.68	63	8811	137308	56145885
Hyperlipidaemia	25.80	14.68	22	8852	18087	56265106
Drug interaction	25.68	14.68	82	8792	209673	56073520
Muscular weakness	25.50	14.68	53	8821	104399	56178794
Alopecia	24.31	14.68	8	8866	293450	55989743
Peripheral swelling	24.17	14.68	4	8870	234722	56048471
Coronary artery disease	22.51	14.68	26	8848	30770	56252423
Joint swelling	22.14	14.68	9	8865	289791	55993402
Pulmonary artery stenosis	21.23	14.68	5	8869	163	56283030
Blood creatinine increased	21.12	14.68	42	8832	80149	56203044
Hypernatraemia	20.84	14.68	13	8861	6607	56276586
Neonatal seizure	20.71	14.68	6	8868	443	56282750
Chromaturia	20.58	14.68	18	8856	15307	56267886
Immunosuppressant drug level increased	20.22	14.68	10	8864	3243	56279950
Haematoma	20.07	14.68	25	8849	31994	56251199
Erysipelas	19.82	14.68	13	8861	7200	56275993
Cerebrovascular accident	19.30	14.68	46	8828	99224	56183969
Otospondylomegaepiphyseal dysplasia	19.26	14.68	4	8870	72	56283121
Angiosclerosis	19.11	14.68	3	8871	9	56283184
Cholestasis	18.47	14.68	22	8852	26891	56256302
Blood urea increased	18.46	14.68	21	8853	24452	56258741
Pleuritic pain	17.66	14.68	12	8862	7045	56276148
Osteonecrosis	17.64	14.68	20	8854	23195	56259998
Product use issue	17.40	14.68	4	8870	186037	56097156
Therapeutic product effect decreased	17.19	14.68	3	8871	169449	56113744
Hepatic cytolysis	17.09	14.68	14	8860	10892	56272301
Bradycardia neonatal	16.90	14.68	6	8868	851	56282342
Cerebral ischaemia	16.69	14.68	11	8863	6139	56277054
Sterile pyuria	16.68	14.68	3	8871	24	56283169
Nephroangiosclerosis	16.66	14.68	4	8870	142	56283051
Hypothyroidism	16.63	14.68	25	8849	38171	56245022
Ocular myasthenia	16.60	14.68	4	8870	144	56283049
Synovitis	16.05	14.68	3	8871	161302	56121891
Foetal exposure during pregnancy	15.97	14.68	23	8851	33800	56249393
Hepatic function abnormal	15.59	14.68	23	8851	34535	56248658
Fasciitis	15.31	14.68	5	8869	551	56282642
Amyotrophic lateral sclerosis	15.29	14.68	6	8868	1122	56282071

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	275.69	16.09	205	8857	77053	31611229
Blood creatine phosphokinase increased	159.77	16.09	116	8946	41858	31646424
Rectal prolapse	80.90	16.09	20	9042	434	31687848
Intraductal papillary mucinous neoplasm	77.83	16.09	20	9042	510	31687772
Myopathy	75.88	16.09	44	9018	10808	31677474
Renal cyst haemorrhage	75.80	16.09	20	9042	567	31687715
Muscle rupture	71.86	16.09	26	9036	2137	31686145
SARS-CoV-2 antibody test positive	59.08	16.09	15	9047	364	31687918
Vena cava injury	57.34	16.09	14	9048	288	31687994
Abdominal wall haemorrhage	56.69	16.09	15	9047	430	31687852
Carotid arteriosclerosis	54.21	16.09	20	9042	1737	31686545
Vascular anastomotic haemorrhage	53.78	16.09	13	9049	256	31688026
Delayed graft function	53.75	16.09	21	9041	2134	31686148
Aortic dilatation	52.99	16.09	18	9044	1227	31687055
Diverticulum intestinal	52.62	16.09	24	9038	3579	31684703
Off label use	50.91	16.09	18	9044	347256	31341026
Perineal cyst	49.37	16.09	12	9050	242	31688040
Gamma-glutamyltransferase increased	48.13	16.09	49	9013	27776	31660506
Renal artery stenosis	46.89	16.09	19	9043	2123	31686159
Vascular compression	45.42	16.09	12	9050	342	31687940
Mean cell volume increased	44.70	16.09	20	9042	2852	31685430
Restless legs syndrome	42.74	16.09	27	9035	7729	31680553
Hyperparathyroidism secondary	42.34	16.09	16	9046	1485	31686797
Amyotrophic lateral sclerosis	40.83	16.09	14	9048	982	31687300
Aortic arteriosclerosis	40.68	16.09	21	9041	4102	31684180
Actinic keratosis	40.42	16.09	21	9041	4158	31684124
Rhabdomyolysis	38.71	16.09	67	8995	63514	31624768
Hepatosplenomegaly	38.67	16.09	20	9042	3923	31684359
Spinal stenosis	37.90	16.09	21	9041	4727	31683555
Glycosylated haemoglobin increased	37.80	16.09	28	9034	10372	31677910
Intervertebral disc space narrowing	37.56	16.09	13	9049	938	31687344
Vertigo	36.94	16.09	39	9023	23046	31665236
Left ventricular hypertrophy	34.21	16.09	23	9039	7309	31680973
Haemorrhoids	33.48	16.09	28	9034	12354	31675928
Spinal osteoarthritis	32.95	16.09	22	9040	6913	31681369
Arteriosclerosis	32.59	16.09	26	9036	10741	31677541
Myocardial infarction	32.44	16.09	88	8974	113366	31574916
Dysuria	31.89	16.09	37	9025	24257	31664025
Vestibular neuronitis	31.32	16.09	8	9054	199	31688083
Swelling of eyelid	30.63	16.09	11	9051	884	31687398
Blood 25-hydroxycholecalciferol decreased	30.45	16.09	8	9054	223	31688059
Face oedema	28.69	16.09	24	9038	10592	31677690
Toxicity to various agents	27.22	16.09	9	9053	181478	31506804
Tendon rupture	27.00	16.09	19	9043	6500	31681782
Aspartate aminotransferase increased	26.94	16.09	57	9005	62662	31625620
General physical health deterioration	26.63	16.09	82	8980	113353	31574929
Blood potassium increased	26.48	16.09	27	9035	15318	31672964
Death	26.41	16.09	39	9023	360530	31327752
Benign prostatic hyperplasia	26.19	16.09	25	9037	13100	31675182
Angina pectoris	26.05	16.09	37	9025	29604	31658678
Vitamin D decreased	25.63	16.09	14	9048	3063	31685219
Activated partial thromboplastin time prolonged	25.18	16.09	20	9042	8205	31680077
Generalised oedema	25.05	16.09	23	9039	11478	31676804
Febrile bone marrow aplasia	23.85	16.09	19	9043	7827	31680455
Fear	23.80	16.09	21	9041	9953	31678329
Coronary artery disease	23.50	16.09	45	9017	46042	31642240
Hepatic steatosis	23.46	16.09	26	9036	16213	31672069
Squamous cell carcinoma of skin	23.44	16.09	21	9041	10153	31678129
Complications of transplanted kidney	21.28	16.09	14	9048	4291	31683991
Presyncope	20.44	16.09	25	9037	17303	31670979
Product dose omission issue	20.30	16.09	3	9059	105583	31582699
Perioral dermatitis	19.86	16.09	5	9057	117	31688165
Large intestine polyp	19.29	16.09	16	9046	6976	31681306
Seizure	18.80	16.09	3	9059	99765	31588517
Congenital inguinal hernia	18.40	16.09	5	9057	159	31688123
Aortic valve incompetence	18.10	16.09	14	9048	5527	31682755
Chronic kidney disease	18.05	16.09	36	9026	37939	31650343
Myocardial ischaemia	17.99	16.09	23	9039	16644	31671638
Funguria	17.83	16.09	4	9058	56	31688226
Renal cyst	16.73	16.09	16	9046	8400	31679882

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	324.85	13.71	269	14003	167623	70746549
Blood creatine phosphokinase increased	245.37	13.71	153	14119	61110	70853062
Rhabdomyolysis	113.64	13.71	117	14155	95643	70818529
Myopathy	110.29	13.71	60	14212	18552	70895620
Gamma-glutamyltransferase increased	84.99	13.71	75	14197	50610	70863562
Renal cyst haemorrhage	80.93	13.71	20	14252	624	70913548
Intraductal papillary mucinous neoplasm	76.82	13.71	20	14252	772	70913400
Off label use	75.13	13.71	28	14244	743032	70171140
SARS-CoV-2 antibody test positive	64.27	13.71	15	14257	365	70913807
Aspartate aminotransferase increased	63.57	13.71	101	14171	126877	70787295
Vena cava injury	61.68	13.71	14	14258	300	70913872
Carotid arteriosclerosis	58.49	13.71	21	14251	2406	70911766
Vascular anastomotic haemorrhage	58.32	13.71	13	14259	256	70913916
Rectal prolapse	58.25	13.71	20	14252	2009	70912163
Amyotrophic lateral sclerosis	56.89	13.71	19	14253	1755	70912417
Abdominal wall haemorrhage	56.43	13.71	15	14257	628	70913544
Muscle rupture	54.90	13.71	22	14250	3403	70910769
Perineal cyst	53.70	13.71	12	14260	239	70913933
Delayed graft function	52.13	13.71	21	14251	3292	70910880
Alanine aminotransferase increased	51.33	13.71	100	14172	147380	70766792
Aortic dilatation	50.21	13.71	17	14255	1637	70912535
Actinic keratosis	47.55	13.71	23	14249	5567	70908605
Vascular compression	46.55	13.71	12	14260	445	70913727
Renal artery stenosis	45.49	13.71	19	14253	3265	70910907
Myocardial infarction	45.35	13.71	104	14168	171541	70742631
Aortic arteriosclerosis	40.15	13.71	23	14249	7846	70906326
Coronary artery disease	40.12	13.71	56	14216	62680	70851492
Diverticulum intestinal	39.68	13.71	23	14249	8018	70906154
Hyperparathyroidism secondary	39.51	13.71	16	14256	2542	70911630
Benign prostatic hyperplasia	39.03	13.71	25	14247	10418	70903754
Mean cell volume increased	38.52	13.71	20	14252	5624	70908548
Hepatosplenomegaly	38.43	13.71	20	14252	5650	70908522
Intervertebral disc space narrowing	35.79	13.71	13	14259	1539	70912633
Rheumatoid arthritis	34.86	13.71	8	14264	291797	70622375
Toxicity to various agents	32.88	13.71	18	14254	382154	70532018
Joint swelling	32.19	13.71	6	14266	253205	70660967
Activated partial thromboplastin time prolonged	31.01	13.71	24	14248	13481	70900691
Arteriosclerosis	30.66	13.71	26	14246	16612	70897560
Blood 25-hydroxycholecalciferol decreased	30.14	13.71	8	14264	333	70913839
Left ventricular hypertrophy	29.90	13.71	21	14251	10181	70903991
Blood potassium increased	29.88	13.71	32	14240	27294	70886878
Completed suicide	29.70	13.71	5	14267	227130	70687042
Glycosylated haemoglobin increased	29.66	13.71	26	14246	17365	70896807
Peripheral swelling	29.24	13.71	6	14266	236557	70677615
Death	29.07	13.71	36	14236	510025	70404147
Acute kidney injury	28.57	13.71	178	14094	474446	70439726
Cerebrovascular accident	28.48	13.71	78	14194	143392	70770780
Spinal osteoarthritis	28.31	13.71	24	14248	15324	70898848
Muscular weakness	28.25	13.71	76	14196	138260	70775912
Squamous cell carcinoma of skin	27.91	13.71	22	14250	12690	70901482
Lactic acidosis	27.52	13.71	48	14224	64976	70849196
Myoglobin blood increased	27.32	13.71	13	14259	3034	70911138
Blood alkaline phosphatase increased	27.14	13.71	45	14227	58476	70855696
Muscle spasms	26.93	13.71	80	14192	153966	70760206
Complications of transplanted kidney	26.73	13.71	16	14256	5918	70908254
Infusion related reaction	26.61	13.71	4	14268	197530	70716642
Drug ineffective	26.32	13.71	99	14173	939653	69974519
Haemorrhoids	26.30	13.71	29	14243	25559	70888613
Fear	25.68	13.71	26	14246	20785	70893387
Jaundice	25.24	13.71	40	14232	50068	70864104
Spinal stenosis	25.18	13.71	22	14250	14631	70899541
Vertigo	24.91	13.71	45	14227	62598	70851574
Vestibular neuronitis	24.63	13.71	8	14264	677	70913495
Swelling of eyelid	24.36	13.71	12	14260	3020	70911152
Hyperkalaemia	24.26	13.71	61	14211	106530	70807642
Tendon rupture	23.82	13.71	19	14253	11150	70903022
Blood creatinine increased	23.80	13.71	73	14199	142928	70771244
Face oedema	22.86	13.71	27	14245	25612	70888560
General physical health deterioration	22.80	13.71	101	14171	235930	70678242
Restless legs syndrome	22.70	13.71	23	14249	18405	70895767
Myocardial ischaemia	22.44	13.71	26	14246	24174	70889998
Product dose omission issue	22.21	13.71	8	14264	217460	70696712
Hepatic steatosis	21.33	13.71	30	14242	33783	70880389
Dysuria	20.95	13.71	35	14237	45759	70868413
Blood urea increased	20.88	13.71	35	14237	45874	70868298
Drug interaction	19.85	13.71	138	14134	381303	70532869
Chromaturia	19.71	13.71	24	14248	23504	70890668
Large intestine polyp	19.25	13.71	17	14255	11459	70902713
Muscle necrosis	19.23	13.71	8	14264	1360	70912812
Presyncope	19.01	13.71	30	14242	37408	70876764
Product use in unapproved indication	18.98	13.71	9	14263	207469	70706703
Renal cyst	18.94	13.71	18	14254	13327	70900845
Hepatic function abnormal	18.82	13.71	42	14230	67954	70846218
Aortic valve incompetence	18.67	13.71	15	14257	8889	70905283
General physical condition	18.38	13.71	3	14269	9	70914163
Product use issue	17.73	13.71	7	14265	179930	70734242
Alopecia	17.56	13.71	9	14263	198481	70715691
Angiosclerosis	17.52	13.71	3	14269	13	70914159
Metabolic acidosis	17.39	13.71	43	14229	74303	70839869
Vitamin D decreased	17.26	13.71	14	14258	8413	70905759
Chronic kidney disease	17.22	13.71	38	14234	61019	70853153
Atrioventricular block first degree	17.05	13.71	16	14256	11657	70902515
Perioral dermatitis	17.00	13.71	5	14267	304	70913868
Blood lactate dehydrogenase increased	16.27	13.71	27	14245	35100	70879072
Pancreatitis acute	16.11	13.71	31	14241	45193	70868979
Blood creatine phosphokinase MB	16.06	13.71	3	14269	23	70914149
Immunosuppressant drug level increased	15.90	13.71	13	14259	7894	70906278
Acute myocardial infarction	15.84	13.71	41	14231	72846	70841326
Haematoma	15.82	13.71	32	14240	48386	70865786
Interstitial lung disease	15.19	13.71	51	14221	104634	70809538
Palmoplantar keratoderma	15.16	13.71	5	14267	444	70913728
Febrile bone marrow aplasia	14.83	13.71	15	14257	11976	70902196
Lipids abnormal	13.94	13.71	5	14267	571	70913601
Congenital aortic dilatation	13.71	13.71	3	14269	54	70914118

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AA04	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN HMG CoA reductase inhibitors
FDA MoA	N0000000121	Hydroxymethylglutaryl-CoA Reductase Inhibitors
FDA EPC	N0000175589	HMG-CoA Reductase Inhibitor
CHEBI has role	CHEBI:35679	antilipemic drugs
CHEBI has role	CHEBI:77255	lethal toxin inhibitors
CHEBI has role	CHEBI:35821	anticholesteremic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Arteriosclerotic vascular disease	indication	72092001
Familial hypercholesterolemia - heterozygous	indication	238079002
Mixed hyperlipidemia	indication	267434003
Slow Progression of Coronary Artery Disease	indication
Cerebrovascular accident	off-label use	230690007
Myocardial Infarction Prevention	off-label use
Primary Prevention of Coronary Heart Disease	off-label use
Prevention of Transient Ischemic Attacks	off-label use
Alcoholism	contraindication	7200002
Low blood pressure	contraindication	45007003
Acute nephropathy	contraindication	58574008
Disorder of muscle	contraindication	129565002	DOID:423
Liver function tests abnormal	contraindication	166603001
Hemorrhagic cerebral infarction	contraindication	230706003
Disease of liver	contraindication	235856003	DOID:409
Rhabdomyolysis	contraindication	240131006
Pregnancy, function	contraindication	289908002
Surgical procedure	contraindication	387713003
Breastfeeding (mother)	contraindication	413712001
Traumatic injury	contraindication	417746004
Uncontrolled Epilepsy	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.05	acidic
pKa2	13.34	acidic
pKa3	13.99	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme	P04035	HMDH_HUMAN	INHIBITOR	IC50	7.55	CHEMBL	DRUG LABEL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6.40	DRUG MATRIX
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN		Kd	4.96	CHEMBL
Nuclear receptor subfamily 1 group I member 3	Nuclear hormone receptor	Q14994	NR1I3_HUMAN				WOMBAT-PK
Sodium/bile acid cotransporter	Transporter	Q14973	NTCP_HUMAN		IC50	4.40	CHEMBL
NAD-dependent protein deacetylase sirtuin-6	Unclassified	Q8N6T7	SIR6_HUMAN		EC50	5.15	CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme		HMDH_RAT		IC50	8.60	CHEMBL

External reference:

ID	Source
D00892	KEGG_DRUG
93957-55-2	SECONDARY_CAS_RN
4020854	VANDF
4023909	VANDF
C0082608	UMLSCUI
CHEBI:38561	CHEBI
115	PDB_CHEM_ID
CHEMBL2220442	ChEMBL_ID
CHEMBL1078	ChEMBL_ID
CHEMBL2218894	ChEMBL_ID
D000077340	MESH_DESCRIPTOR_UI
DB01095	DRUGBANK_ID
23663976	PUBCHEM_CID
2951	IUPHAR_LIGAND_ID
6547	INN_ID
4L066368AS	UNII
151972	RXNORM
1724	MMSL
189348	MMSL
4757	MMSL
d03183	MMSL
004439	NDDF
004440	NDDF
387585004	SNOMEDCT_US
412392009	SNOMEDCT_US
96307003	SNOMEDCT_US
CHEMBL103585	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LescolXL	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0354	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	30 sections
LescolXL	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0354	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	30 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7442	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7442	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7443	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7443	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7446	TABLET, FILM COATED, EXTENDED RELEASE	80 mg	ORAL	ANDA	28 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0093-7446	TABLET, FILM COATED, EXTENDED RELEASE	80 mg	ORAL	ANDA	28 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8020	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8021	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2580	TABLET, FILM COATED, EXTENDED RELEASE	80 mg	ORAL	ANDA	30 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0527-2580	TABLET, FILM COATED, EXTENDED RELEASE	80 mg	ORAL	ANDA	30 sections
FLUVASTATIN SODIUMER	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8017	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA authorized generic	27 sections
LESCOL	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3329	CAPSULE	20 mg	ORAL	NDA	15 sections
LESCOL	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4224	CAPSULE	40 mg	ORAL	NDA	15 sections
LESCOL XL	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4601	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	15 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8737	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8737	CAPSULE	40 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8812	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8812	CAPSULE	20 mg	ORAL	ANDA	26 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	68151-1326	CAPSULE	20 mg	ORAL	ANDA	25 sections
Fluvastatin Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	68151-1334	CAPSULE	40 mg	ORAL	ANDA	25 sections
Lescol XL	HUMAN PRESCRIPTION DRUG LABEL	1	68151-4471	TABLET, EXTENDED RELEASE	80 mg	ORAL	NDA	26 sections